Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)’s share price reached a new 52-week high and low on Thursday . The company traded as low as $21.00 and last traded at $20.55, with a volume of 247191 shares traded. The stock had previously closed at $20.50.
A number of equities analysts have weighed in on the stock. Stifel Nicolaus raised shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and increased their price target for the stock from $18.00 to $21.00 in a research note on Thursday, February 22nd. BidaskClub raised shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, April 4th. ValuEngine raised shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, April 3rd. Finally, Zacks Investment Research raised shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company’s stock. Momenta Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $15.33.
The stock has a market capitalization of $1,552.54, a PE ratio of -17.00 and a beta of 1.64.
Momenta Pharmaceuticals (NASDAQ:MNTA) last released its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.12. Momenta Pharmaceuticals had a negative net margin of 63.43% and a negative return on equity of 23.62%. The company had revenue of $64.60 million during the quarter, compared to analyst estimates of $66.59 million. During the same quarter in the prior year, the business earned $0.60 earnings per share. The business’s quarterly revenue was up 88.9% compared to the same quarter last year. equities analysts predict that Momenta Pharmaceuticals, Inc. will post -1.27 EPS for the current year.
In other news, SVP Bruce Leicher sold 1,861 shares of the stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $16.00, for a total value of $29,776.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Craig A. Wheeler sold 43,334 shares of the stock in a transaction on Tuesday, April 10th. The stock was sold at an average price of $19.00, for a total transaction of $823,346.00. The disclosure for this sale can be found here. Insiders sold 128,682 shares of company stock valued at $2,265,236 in the last three months. Company insiders own 4.40% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc grew its holdings in Momenta Pharmaceuticals by 21.4% during the 3rd quarter. Legal & General Group Plc now owns 154,060 shares of the biotechnology company’s stock valued at $2,851,000 after purchasing an additional 27,173 shares in the last quarter. Wells Fargo & Company MN grew its holdings in Momenta Pharmaceuticals by 6.8% during the 3rd quarter. Wells Fargo & Company MN now owns 219,520 shares of the biotechnology company’s stock valued at $4,062,000 after purchasing an additional 13,921 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in Momenta Pharmaceuticals by 9.4% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 391,792 shares of the biotechnology company’s stock valued at $7,249,000 after purchasing an additional 33,737 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in Momenta Pharmaceuticals during the 3rd quarter valued at $1,067,000. Finally, Sicart Associates LLC acquired a new stake in Momenta Pharmaceuticals during the 4th quarter valued at $279,000. 97.64% of the stock is owned by institutional investors.
WARNING: “Momenta Pharmaceuticals (MNTA) Reaches New 52-Week High and Low at $21.00” was first posted by Macon Daily and is owned by of Macon Daily. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://macondaily.com/2018/04/19/momenta-pharmaceuticals-mnta-reaches-new-52-week-high-and-low-at-21-00.html.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.